Uncategorized

Bionyra brings in $165M for next-generation immune drugs

The biotech, co-founded by Sofinnova Partners and a former Sanofi immunology R&D head, is testing new biologics against common immune conditions.

Published

5 months ago

on

June 22, 2026

By

Temp User

The biotech, co-founded by Sofinnova Partners and a former Sanofi immunology R&D head, is testing new biologics against common immune conditions.

Related Topics:

Leave a Reply

Uncategorized8 months ago

Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Endpoints News8 months ago

Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Uncategorized7 months ago

Optical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
Uncategorized6 months ago

Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
Uncategorized5 months ago

Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
Fierce Biotech8 months ago

Scientists turn pig semen extract into eye drops that kill cancer in mice

Exit mobile version